FAERS analysis finds distinct adverse event patterns for tirzepatide and semaglutide

The wire

1. 01Researchers analysed 151,654 tirzepatide and 64,987 semaglutide FAERS reports from May 2022 to June 2026, finding semaglutide GI ROR 3.64 and metabolic ROR 4.25, with tirzepatide hypoglycaemia RORR 1.91.
2. 02Reporter identity shifted the picture: healthcare professionals filed 23.42% of semaglutide reports versus 5.04% for tirzepatide, and in that cohort tirzepatide GI ROR rose to 2.53 and semaglutide showed eye disorder signals.
3. 03Pancreatitis signalled for both but attenuated to equivalence within type 2 diabetes; the authors call all findings hypothesis-generating pending defined exposure denominators.

From the source

Real-World Adverse Event Reporting Patterns of Tirzepatide Versus Semaglutide: A Stratified Study of General and Healthcare Professional Cohorts in FAERS

Diabetes, obesity & metabolism · 2026 Sep 21 · Liu X, Wang W et al.